Retour

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Calendar Calendar of Events

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire Inc. • 07/05/2024 à 13:30:00
Lexeo Therapeutics, Inc. Common Stock
Address: 345 PARK AVENUE SOUTH
Postal Code: 10010
City: NEW YORK
State: NY
Phone Number: (212) 547-9879
Website: https://www.lexeotx.com
Status: Active
Company Info

Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.

List Date2023-11-03
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001907108
Composite figiBBG00YB1C8M5
Share Class figiBBG00YB1C8N4
Market Cap456,292,973 USD
SIC Code2836
SIC DescriptionBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Total Employees61
Share Class Shares Outstanding32950000
Weighted Shares Outstanding32945341
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
13.87
13.97
13.946
14.165
13.564
Variance
-0.72%
0.18%
-0.17%
4.42%
3.5%
Open
13.97
13.945
13.97
13.565
13.105
Highest
14.27
15.06
14.829
14.4
13.917
Lowest
14.27
15.015
14.815
14.395
13.541
History
PeriodVarhighestlowest
1 week
5.84%
13.917
13.541
1 month
13.24%
13.14
12.448
3 month
-17.98%
17.682
12.448
6 month
24.9%
12.585
10
1 year
46%
10.34
9
3 year
46%
10.34
9
5 year
46%
10.34
9
10 year
46%
10.34
9
Calendar
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
15:30
United States
-17800.000
15:30
United States
-60000.000
15:30
United States
53700.000
15:30
United States
-135800.000
★★
15:30
United States
4400.000
15:30
United States
215400.000
15:30
United States
-31400.000
15:30
United States
62600.000
15:30
United States
1300.000
15:30
United States
-9700.000
15:30
United States
199600.000
★★
15:30
United States
15:30
United States
15:30
United States
News Stream
Stocks Earnings Releases and Operating Results
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc. • 1w ago
Health Health
Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN (LX2006) to support regulatory discussions
GlobeNewswire Inc. • 3w ago
Government Government News
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006
GlobeNewswire Inc. • 1mo ago
Stocks Financing Agreements
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
GlobeNewswire Inc. • 2mo ago
Analyst Analyst Ratings
RBC Capital has decided to maintain its Outperform rating of Lexeo Therapeutics (NASDAQ:LXEO) and raise its price target from $22.00 to $24.00. Shares of Lexeo Therapeutics are trading up 7.11% over the last 24 hours, at $15.52 per share. A move to $24.00 would account for a 54.64% increase from the current share price. About Lexeo Therapeutics Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. ...Full story available on Benzinga.com
Benzinga • 2mo ago
Stocks Earnings Releases and Operating Results
Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027
GlobeNewswire Inc. • 2mo ago
Stocks Changes in company's own shares
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel company), Eventide Asset Management and Novo Holdings A/S. Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel company), Eventide Asset Management and Novo Holdings A/S.
GlobeNewswire Inc. • 2mo ago
Management Directors and Officers
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
GlobeNewswire Inc. • 3mo ago
News Clinical Study
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic
GlobeNewswire Inc. • 5mo ago
See All

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT